The morbidity associated with persistent inflammation in inflammatory bowel disease (IBD) has spurred a shift in the goals of therapy from the control of symptoms to achieving corticosteroid-free sustained complete remission including endoscopic remission.1–4 Since the approval of the first tumor necrosis factor antagonist (anti-TNF) for IBD treatment about 2 decades ago, several other biologics and small molecule drugs (SMDs) including vedolizumab (VDZ), ustekinumab (UST), and tofacitinib (Tofa) have been approved for patients with moderate-to-severe IBD. The gene discussed is TNF; the disease is inflammatory bowel disease.